Altogether, this study demonstrates the potential and promise of TH301, a novel CRY2 molecular stabilizer, to act as a new therapeutic agent for Pancreatic Ductal Adeno-Carcinoma (PDAC). Here, CRY2 is linked to pancreatic ductal adenocarcinoma.